About | HeinOnline Law Journal Library | HeinOnline Law Journal Library | HeinOnline
LOG IN
LOG IN

2 Nanotech. L. & Bus. 139 (2005)
Global Developments in Nano-Enabled Drug Delivery Markets

handle is hein.journals/nantechlb2 and id is 145 raw text is: Global Developments in Nano-Enabled Drug Delivery Markets MICHAEL MORAD* ABSTRACT The drug delivery industry is at an inflection point in its celebrated history, and a period of rapid change looms on the horizon. As drug delivery companies increasingly focus e/Jbrts upstream, they will collaborate with the drug discovery industry to an even greater degree. At the same time, industrial nanotechnology is bearing fruit Jbr investors and presents new opportunities for the drug delivery industry. Nano-enabled drug delivery systems are rapidly emerging to address pharmaceutical industry challenges with regard to solubility, cost-reduction, marketing, higher disease targeting and lifecycle extension. A combination ofjfactors within the drug delivery and nanotechnology industries are producing a greater synergy between nanotechnology and advanced drug delivery systems, including early success of nanotechnology commercial applications, intense patent competition, successful governmental nanotechnology initiatives around the globe and general excitement about nanotechnology and its application. While the industry undoubtedly faces challenges, there are silver linings and the prospect of immense opportunity. INTRODUCTION ccording to Deutsche Bank Securities, the average drug delivery stock has plummeted roughly 55% during the last five years. Simultaneously, over the next decade, several blockbuster drugs will go off patent, resulting in an estimated loss of $30-$40 billion in annual product revenues as generic equivalent drugs enter the market. With double digit growth over the past two decades, the industry's success has spawned intense competition. Coupled with an evolving regulatory framework, meeting Wall Street's aggressive growth expectations becomes increasingly difficult. These and other factors are accelerating the industry's constant need to build the pipeline of new compounds and quickly enter new markets. In a sentence-the drug delivery industry is at an inflection point in its celebrated history, and rapid change is inevitable. Leading drug delivery companies will continue to grow via their traditional core business, through mergers and acquisitions, and internal development of high-value compounds. While drug delivery traditionally has been seen as a drug lifecycle management tool, industry leaders are now focusing their efforts upstream. This type of collaboration requires drug delivery companies to work more intimately * Michael Moradi is an Associate Analyst, NanoMarkets, L.C. (www.nanomarkets.net) and Managing Director, Venture Development Associates, L.L.C. (www.VdaOK.com). He can be reached at mmoradi@cox.net and (405) 209-1850. VOLUME 2.2 (2005)

What Is HeinOnline?

HeinOnline is a subscription-based resource containing thousands of academic and legal journals from inception; complete coverage of government documents such as U.S. Statutes at Large, U.S. Code, Federal Register, Code of Federal Regulations, U.S. Reports, and much more. Documents are image-based, fully searchable PDFs with the authority of print combined with the accessibility of a user-friendly and powerful database. For more information, request a quote or trial for your organization below.



Short-term subscription options include 24 hours, 48 hours, or 1 week to HeinOnline.

Purchase Access

Contact us for annual subscription options:

Contact Us

Already a HeinOnline Subscriber?

Log In

profiles profiles most